Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 23, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)

New study arm (Part D) is part of the broad clinical development plan of the ITM-91/ITM-94 theranostic program in patients with Carbonic Anhydrase IX (CAIX)-expressing tumors Part D builds on...
September 12, 2024 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors

ITM gains exclusive global development and commercialization rights to Debiopharm’s first-in-class, peptide-based theranostic pair which combines therapeutic compound, Debio 0228 ([177Lu]Lu-DPI-4452)...